Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway

被引:97
作者
Liu, XH
Kirschenbaum, A
Lu, M
Yao, S
Klausner, A
Preston, C
Holland, JF
Levine, AC
机构
[1] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA
关键词
COX-2; gp130; IL-6; soluble IL-6 receptor; PGE(2); prostate cancer; Stat-3;
D O I
10.1006/bbrc.2001.6188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclooxygenase (COX)-2 expression and prostaglandin E-2 (PGE(2)) secretion are increased in prostatic intraepithelial neoplasia (PIN) and prostate cancer. PGE(2) biosynthesis by cyclooxygenase (COX)-2 plays a pivotal role in inflammation and carcinogenesis. One of the critical proinflammatory cytokines in the prostate is interleukin-6 (IL-6). We hypothesized that increased expression of COX-2, with resultant increased levels of PGE(2) in human PIN cells, activates the IL-6 signaling pathway. We demonstrate an autocrine up-regulation of PGE(2) mediated by IL-6 in a human PIN cell line. We further demonstrate that PGE stimulates soluble IL-6 receptor (sIL-6R) release, gp130 dimerization, Stat-3 protein phosphorylation, and DNA binding activity. These events, induced by PGE2, lead to increased PIN cell growth. Treatment of PIN cells with a selective COX-2 inhibitor decreases cell growth. Finally, PGE(2)-stimulated PIN cell growth was abrogated by the addition of IL-6 neutralizing antibodies. These data provide mechanistic evidence that increased expression of COX-2/PGE(2) contributes to prostate cancer development and progression via activation of the IL-6 signaling pathway. (C) 2002 Elsevier Science.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 33 条
[1]  
Akarasereenont Pravit, 1999, Journal of the Medical Association of Thailand, V82, P876
[2]  
AKIRA S, 1990, CHEM IMMUNOL, V51, P299
[3]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[4]  
Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO
[5]  
2-W
[6]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[7]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[8]  
Chung TDK, 1999, PROSTATE, V38, P199
[9]   Proliferative inflammatory atrophy of the prostate - Implications for prostatic carcinogenesis [J].
De Marzo, AM ;
Marchi, VL ;
Epstein, JI ;
Nelson, WG .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1985-1992
[10]   Cyclooxygenase in biology and disease [J].
Dubois, RN ;
Abramson, SB ;
Crofford, L ;
Gupta, RA ;
Simon, LS ;
Van De Putte, LBA ;
Lipsky, PE .
FASEB JOURNAL, 1998, 12 (12) :1063-1073